Meeting
2022 ASCO Genitourinary Cancers Symposium
Stage I testicular cancer: Five-year follow-up rates and reasons for non-adherence.
Authors
Tim Karmas
Dalhousie University, Halifax, NS, Canada
Tim Karmas , Patrick Holland , Kara Matheson , Lori Wood
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 412)
DOI
10.1200/JCO.2022.40.6_suppl.412
Abstract #
412
Poster Bd #
L12
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
WATChmAN: A randomized trial of virtual surveillance versus standard in-person care for clinical stage I testicular cancer.
First Author: Robert James Hamilton
Poster
2011 ASCO Annual Meeting
Evaluation of low-dose CT scans for surveillance in stage I testicular cancer.
First Author: P. W. M. Chung
Poster
2024 ASCO Genitourinary Cancers Symposium
Association of DAZL expression with risk of recurrence in clinical stage 1 testicular germ cell tumors.
First Author: Alok Tewari
Poster
2023 ASCO Genitourinary Cancers Symposium
A multicenter prospective validation study of the 3-cm cut-off in stage I seminoma (S3MI-PT).
First Author: Mario Fontes-Sousa